MétaCan
Menu
Back to cohort
Record W3177400281

Capsaicin for Acute or Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness [Internet]

2020· review· en· W3177400281 on OpenAlexaboutno aff
Srabani Banerjee, Suzanne McCormack

Bibliographic record

Venuenot available
Typereview
Languageen
FieldNeuroscience
TopicIon Channels and Receptors
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineNociceptorChronic painCapsaicinNeuropathic painTRPV1AnalgesicAnesthesiaNociceptionInternal medicineTransient receptor potential channelPhysical therapyReceptor
DOInot available

Abstract

fetched live from OpenAlex

Pain is a common experience. Generally, acute pain is defined as lasting less than three months, and chronic pain is defined as pain lasting three months or longer. Acute pain includes pain from sprains, strains, and tendonitis; and muscle aches. Chronic pain includes pain associated with osteoarthritis (OA), neuropathic pain (NP), and back pain. According to the Canadian Community Health Survey of individuals during the period 2007 to 2008, the prevalence of chronic pain in adults over the age of 18 years was 18.9% in Canada, and ranged between 16% and 22% for the different provinces. Pain is associated with reduced quality of life, absenteeism from work, and substantial healthcare costs.There are several treatment options for managing pain; both pharmacological and non-pharmacological options. A variety of pharmacological options such as non-steroidal anti-inflammatory drugs (NSAIDs), local anesthetics, tricyclic antidepressants, and capsaicin have been used for pain management., Capsaicin, which is found in chili peppers, has been used as a topical agent to relieve pain. It is a transient receptor potential vanilloid 1 receptor (TRPV1) agonist; it binds to nociceptors (sensory receptors responsible for sending signals that cause the perception of pain) in the skin, specifically to the TRVP1 receptor. This binding initially results in depolarization, initiation of action potential, and pain signal transmission to the spinal cord, and subsequently causes desensitization of the sensory axons and inhibition of pain transmission.– There are various formulations for capsaicin: cream, gel, lotion and patch. It is available as low concentration (e.g., 0.025%, 0.075%, and 0.25%) and high concentration (e.g., 8%) product.– Several capsaicin products are available over-the-counter in Canada. According to a report dated 2018, capsaicin is available in Canada as a cream (0.025%, 0.05%, and 0.075%), gel (0.025%), and patch (0.025%), as well as in creams, gels, or lotions (0.025% or 0.035%) in combination with other active ingredients. There appears to be some uncertainty regarding the therapeutic efficacy of capsaicin for the management of pain.A recent CADTH rapid response report, presented a summary and critical appraisal of evidence-based guidelines regarding capsaicin products for the treatment of acute and chronic non-cancer pain. There was variability in the recommendations for use of capsaicin for the management of pain due to OA. Two guidelines recommended the use of capsaicin (8%) patch as second line therapy for NP. The purpose of this report is to review the clinical effectiveness, safety and cost-effectiveness of capsaicin products for the treatment of acute and chronic non-cancer pain.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.765
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0040.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0060.001
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.178
GPT teacher head0.488
Teacher spread0.311 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2020
Admission routes1
Has abstractyes

Explore more

Same topicIon Channels and ReceptorsFrench-language works237,207